报价延迟最少15分钟:2026/01/07 12:25 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
799.795 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
41.72/46.12
|
|
企业价值
84.32B
|
| 资产负债 |
|
每股账面净值
294.56
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
14.20B
|
|
每股收益
124.62
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
